Biotech Most Active Stocks: Geron Corporation (NASDAQ:GERN), Pfizer Inc. (NYSE:PFE), OXiGENE Inc (NASDAQ:OXGN), Gilead Sciences (NASDAQ:GILD)

Geron Corporation (NASDAQ:GERN) got bad news about its key imetelstat drug, as the FDA issued a clinical hold on the treatment for multiple myeloma and essential thrombocythemia. Geron Corporation (NASDAQ:GERN) stock performance was -61.59% in last session and finished the day at $1.69. Traded volume was 46,444,384 million shares in the last session and the average volume of the stock remained 4.64 million shares. The … Continue reading Biotech Most Active Stocks: Geron Corporation (NASDAQ:GERN), Pfizer Inc. (NYSE:PFE), OXiGENE Inc (NASDAQ:OXGN), Gilead Sciences (NASDAQ:GILD)

Biotech Unusual Volume Stocks: Arca Biopharma (NASDAQ:ABIO), Biota Pharmaceuticals (NASDAQ:BOTA), Lpath (NASDAQ:LPTN), La Jolla Pharmaceutical (NASDAQ:LJPC)

Arca Biopharma Inc (NASDAQ:ABIO) focuses on developing genetically targeted therapies for cardiovascular disease. Its lead product candidate, Gencaro, is an investigational, pharmacologically unique beta-blocker and mild vasodilator being developed for the prevention of atrial fibrillation in patients with heart failure and reduced left ventricular ejection fraction. Arca Biopharma Inc (NASDAQ:ABIO) stock performance was 11.34% in last session and finished the day at $2.16. Traded volume … Continue reading Biotech Unusual Volume Stocks: Arca Biopharma (NASDAQ:ABIO), Biota Pharmaceuticals (NASDAQ:BOTA), Lpath (NASDAQ:LPTN), La Jolla Pharmaceutical (NASDAQ:LJPC)

On March 5, 2014, Opexa Therapeutics, Inc. (NASDAQ:OPXA) entered into a First Amendment to Sales Agreement (the “First Amendment”) with Meyers Associates, L.P. (doing business as Brinson Patrick, a division of Meyers Associates, L.P.) (the “New Sales Manager”) and Brinson Patrick Securities Corporation (the “Original Sales Manager”). Pursuant to the First Amendment, the Sales Agreement dated September 6, 2012 by and between the Company and … Continue reading Biotech Most Volatile Stocks: Opexa Therapeutics (NASDAQ:OPXA), Intrexon (NYSE:XON), Chimerix (NASDAQ:CMRX), NewLink Genetics (NASDAQ:NLNK)

Geron Corporation (NASDAQ:GERN) said the US Food and Drug Administration ordered a halt to trials of a cancer drug over concerns about potential liver damage. Geron Corporation (NASDAQ:GERN) stock performance was -61.59% in last session and finished the day at $1.69. Traded volume was 46,444,384 million shares in the last session and the average volume of the stock remained 4.64 million shares. The beta of … Continue reading Biotech Top Losers: Geron Corporation (NASDAQ:GERN), Synta Pharmaceuticals (NASDAQ:SNTA), Northwest Biotherapeutics (NASDAQ:NWBO), AEterna Zentaris (NASDAQ:AEZS)

4:30 p.m. Eastern Time (1:30 p.m. Pacific) to discuss its full year and fourth quarter 2013 financial results and provide a review of its pipeline of products in development. Oncothyreon Inc. (USA) (NASDAQ:ONTY) stock performance was 1.92% in last session and finished the day at $3.72. Traded volume was 1.16 million shares in the last session and the average volume of the stock remained 904,463.00 … Continue reading Biotech Stocks Touching New Highs: Oncothyreon (NASDAQ:ONTY), IGI Laboratories (NYSEMKT:IG), TG Therapeutics (NASDAQ:TGTX), Receptos Inc. (NASDAQ:RCPT)

Biopharmaceutical giant Oxigene Inc (NASDAQ:OXGN) y reported its experimental drug Zybrestat, combined with Roche’s cancer drug Avastin, significantly slowed progression of recurrent ovarian cancer. OXiGENE Inc (NASDAQ:OXGN) stock performance was 77.27% in last session and finished the day at $4.29. Traded volume was 29,290,814 million shares in the last session and the average volume of the stock remained 569.72 million shares. The beta of the … Continue reading Biotech Top Gainers: OXiGENE Inc (NASDAQ:OXGN), Cell Therapeutics Inc (NASDAQ:CTIC), Arca Biopharma Inc (NASDAQ:ABIO), NPS Pharmaceuticals (NASDAQ:NPSP)